Literature DB >> 25873574

Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder.

Douglas A Mata1, Susan Groshen, Friedrich-Carl Von Rundstedt, Donald G Skinner, Walter M Stadler, Richard J Cote, John P Stein, Seth P Lerner.   

Abstract

BACKGROUND AND OBJECTIVES: Previous studies have shown that variability in surgical technique can affect the outcomes of cooperative group trials. We analyzed measures of surgical quality and clinical outcomes in patients enrolled in the p53-MVAC trial.
METHODS: We performed a post-hoc analysis of patients with pT1-T2N0M0 urothelial carcinoma of the bladder following radical cystectomy (RC) and bilateral pelvic and iliac lymphadenectomy (LND). Measures of surgical quality were examined for associations with time to recurrence (TTR) and overall survival (OS).
RESULTS: We reviewed operative and/or pathology reports for 440 patients from 35 sites. We found that only 31% of patients met all suggested trial eligibility criteria of having ≥15 lymph nodes identified in the pathologic specimen (LN#) and having undergone both extended and presacral LND. There was no association between extent of LND, LN#, or presacral LND and TTR or OS after adjustment for confounders and multiple testing.
CONCLUSIONS: We demonstrated that there was substantial variability in surgical technique within a cooperative group trial. Despite explicit entry criteria, many patients did not undergo per-protocol LNDs. While outcomes were not apparently affected, it is nonetheless evident that careful attention to study design and quality monitoring will be critical to successful future trials.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Carcinoma; adjuvant; chemotherapy; cystectomy; genes; p53; transitional cell

Mesh:

Year:  2015        PMID: 25873574      PMCID: PMC4602027          DOI: 10.1002/jso.23903

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  15 in total

1.  Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.

Authors:  Walter M Stadler; Seth P Lerner; Susan Groshen; John P Stein; Shan-Rong Shi; Derek Raghavan; David Esrig; Gary Steinberg; David Wood; Laurence Klotz; Craig Hall; Donald G Skinner; Richard J Cote
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

2.  p53 and treatment of bladder cancer.

Authors:  R J Cote; D Esrig; S Groshen; P A Jones; D G Skinner
Journal:  Nature       Date:  1997-01-09       Impact factor: 49.962

3.  A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.

Authors:  Michael B Farnell; Randall K Pearson; Michael G Sarr; Eugene P DiMagno; Lawrence J Burgart; Tamela R Dahl; Nathan Foster; Daniel J Sargent
Journal:  Surgery       Date:  2005-10       Impact factor: 3.982

4.  Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial.

Authors:  Friedrich-Carl von Rundstedt; Douglas A Mata; Susan Groshen; John P Stein; Donald G Skinner; Walter M Stadler; Richard J Cote; Oleksandr N Kryvenko; Guilherme Godoy; Seth P Lerner
Journal:  BJU Int       Date:  2015-03-25       Impact factor: 5.588

5.  Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic.

Authors:  K Weingärtner; A Ramaswamy; A Bittinger; E W Gerharz; D Vöge; H Riedmiller
Journal:  J Urol       Date:  1996-12       Impact factor: 7.450

Review 6.  Role and extent of lymphadenectomy during radical cystectomy for invasive bladder cancer.

Authors:  Robert Svatek; Pascal Zehnder
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

7.  Surgical factors influence bladder cancer outcomes: a cooperative group report.

Authors:  Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

8.  The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results.

Authors:  S P Lerner; D G Skinner; G Lieskovsky; S D Boyd; S L Groshen; A Ziogas; E Skinner; P Nichols; B Hopwood
Journal:  J Urol       Date:  1993-04       Impact factor: 7.450

9.  Accumulation of nuclear p53 and tumor progression in bladder cancer.

Authors:  D Esrig; D Elmajian; S Groshen; J A Freeman; J P Stein; S C Chen; P W Nichols; D G Skinner; P A Jones; R J Cote
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

10.  Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference.

Authors:  D G Skinner
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

View more
  4 in total

1.  Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database.

Authors:  Mahir Maruf; Abhinav Sidana; Stephanie Purnell; Amit L Jain; Sam J Brancato; Piyush K Agarwal
Journal:  Int Urol Nephrol       Date:  2017-12-23       Impact factor: 2.370

Review 2.  Lymph node dissection in bladder cancer: Where do we stand?

Authors:  Cory M Hugen; Siamak Daneshmand
Journal:  World J Urol       Date:  2015-12-28       Impact factor: 4.226

3.  Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study.

Authors:  James W F Catto; Pramit Khetrapal; Gareth Ambler; Rachael Sarpong; Muhammad Shamim Khan; Melanie Tan; Andrew Feber; Simon Dixon; Louise Goodwin; Norman R Williams; John McGrath; Edward Rowe; Anthony Koupparis; Chris Brew-Graves; John D Kelly
Journal:  BMJ Open       Date:  2018-08-08       Impact factor: 2.692

4.  Editorial concerning "Pelvic lymph node dissection may be limited on the contralateral side in strictly unilateral bladder cancer without compromising oncological radicality".

Authors: 
Journal:  Bladder Cancer       Date:  2016-01-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.